|
Achieved 6.6 billion won in operating profit for Q1, up 17% year-on-year
2021.05.12
|
|---|
|
The company continued its growth momentum in 2021.
In the first quarter of 2021, it achieved an operating profit of 6.6 billion won, representing a 17% increase year-on-year. Revenue rose 11% to 39.4 billion won, while net profit also increased 10% to 4 billion won.
The company attributed its overall performance improvement to the success of its strategic focus on core product lines and systematic distribution network management, both of which have been in place since the previous year. Steady results continue through the company’s management efficiency strategy, which includes proactive risk management measures.
Sales of Zero be Capsule, a fat absorption inhibitor launched in 2020, and Avatri Tablet, a triple combination drug for hypertension and hyperlipidemia, have been steadily growing. In 2021, the company further accelerated growth with the domestically exclusive launch of “Migbos Film-Coated Tablet.”
Increased sales of core products and improvements in the distribution structure continue to drive sustainable performance growth. With the completion of the company’s Industry-Academia Research Center in Pangyo Second Techno Valley, its R&D capabilities have been further strengthened, enabling the development of a broader range of products to sustain long-term growth.
|


Home